Silence Therapeutics said this week that it has been issued a Japanese patent covering its core RNAi technology.
The patent, No. 4,705,370, is entitled “Further Novel Forms of Interfering RNA Molecules,” and claims siRNAs containing proprietary 2’-O-methyl structures.
“The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents … [a] success in our proactive ongoing intellectual property strategy,” Silence CEO Philips Haworth said in a statement.